Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility
Atopic dermatitis can result from loss of structural proteins in the outermost epidermal layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, we chemically induced tumours in EPI−/− mice, which lack three barrier proteins—Envoplakin, Periplakin, and Inv...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2014-05-01
|
| Series: | eLife |
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/01888 |
| _version_ | 1811200300169560064 |
|---|---|
| author | Sara Cipolat Esther Hoste Ken Natsuga Sven R Quist Fiona M Watt |
| author_facet | Sara Cipolat Esther Hoste Ken Natsuga Sven R Quist Fiona M Watt |
| author_sort | Sara Cipolat |
| collection | DOAJ |
| description | Atopic dermatitis can result from loss of structural proteins in the outermost epidermal layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, we chemically induced tumours in EPI−/− mice, which lack three barrier proteins—Envoplakin, Periplakin, and Involucrin. EPI−/− mice were highly resistant to developing benign tumours when treated with 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). The DMBA response was normal, but EPI−/− skin exhibited an exaggerated atopic response to TPA, characterised by abnormal epidermal differentiation, a complex immune infiltrate and elevated serum thymic stromal lymphopoietin (TSLP). The exacerbated TPA response could be normalised by blocking TSLP or the immunoreceptor NKG2D but not CD4+ T cells. We conclude that atopy is protective against skin cancer in our experimental model and that the mechanism involves keratinocytes communicating with cells of the immune system via signalling elements that normally protect against environmental assaults. |
| first_indexed | 2024-04-12T02:02:29Z |
| format | Article |
| id | doaj.art-7127dd80ee864c258ae99f7d7c316752 |
| institution | Directory Open Access Journal |
| issn | 2050-084X |
| language | English |
| last_indexed | 2024-04-12T02:02:29Z |
| publishDate | 2014-05-01 |
| publisher | eLife Sciences Publications Ltd |
| record_format | Article |
| series | eLife |
| spelling | doaj.art-7127dd80ee864c258ae99f7d7c3167522022-12-22T03:52:38ZengeLife Sciences Publications LtdeLife2050-084X2014-05-01310.7554/eLife.01888Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibilitySara Cipolat0Esther Hoste1Ken Natsuga2Sven R Quist3Fiona M Watt4Centre for Stem Cells and Regenerative Medicine, King's College London, London, United Kingdom; Cancer Research UK Cambridge Research Institute, Cambridge, United KingdomCentre for Stem Cells and Regenerative Medicine, King's College London, London, United Kingdom; Cancer Research UK Cambridge Research Institute, Cambridge, United KingdomCancer Research UK Cambridge Research Institute, Cambridge, United Kingdom; Department of Dermatology, Hokkaido University, Sapporo, JapanCancer Research UK Cambridge Research Institute, Cambridge, United Kingdom; Department of Dermatology and Venereology, Otto von Guericke University Magdeburg, Magdeburg, GermanyCentre for Stem Cells and Regenerative Medicine, King's College London, London, United KingdomAtopic dermatitis can result from loss of structural proteins in the outermost epidermal layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, we chemically induced tumours in EPI−/− mice, which lack three barrier proteins—Envoplakin, Periplakin, and Involucrin. EPI−/− mice were highly resistant to developing benign tumours when treated with 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). The DMBA response was normal, but EPI−/− skin exhibited an exaggerated atopic response to TPA, characterised by abnormal epidermal differentiation, a complex immune infiltrate and elevated serum thymic stromal lymphopoietin (TSLP). The exacerbated TPA response could be normalised by blocking TSLP or the immunoreceptor NKG2D but not CD4+ T cells. We conclude that atopy is protective against skin cancer in our experimental model and that the mechanism involves keratinocytes communicating with cells of the immune system via signalling elements that normally protect against environmental assaults.https://elifesciences.org/articles/01888skineczemacancer |
| spellingShingle | Sara Cipolat Esther Hoste Ken Natsuga Sven R Quist Fiona M Watt Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility eLife skin eczema cancer |
| title | Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility |
| title_full | Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility |
| title_fullStr | Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility |
| title_full_unstemmed | Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility |
| title_short | Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility |
| title_sort | epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility |
| topic | skin eczema cancer |
| url | https://elifesciences.org/articles/01888 |
| work_keys_str_mv | AT saracipolat epidermalbarrierdefectslinkatopicdermatitiswithalteredskincancersusceptibility AT estherhoste epidermalbarrierdefectslinkatopicdermatitiswithalteredskincancersusceptibility AT kennatsuga epidermalbarrierdefectslinkatopicdermatitiswithalteredskincancersusceptibility AT svenrquist epidermalbarrierdefectslinkatopicdermatitiswithalteredskincancersusceptibility AT fionamwatt epidermalbarrierdefectslinkatopicdermatitiswithalteredskincancersusceptibility |